How Safe are COVID-19 Vaccines in Immune-Mediated Inflammatory Diseases? The SUCCEED Study
Authors:
- Olga TsyrukOTOlga Tsyruk
- Gilaad G. KaplanGKGilaad G. Kaplan
- Paul R FortinPFPaul R Fortin
- Carol A HitchonCHCarol A Hitchon
- Vinod ChandranVCVinod Chandran
- Maggie J. LarchéMLMaggie J. Larché
- Antonio Avina-ZubietaAAAntonio Avina-Zubieta
- Gilles BoireGBGilles Boire
- Inés ColmegnaICInés Colmegna
- Diane LacailleDLDiane Lacaille
- Nadine LalondeNLNadine Lalonde
- Laurie ProulxLPLaurie Proulx
Preprint
- 5 August 2024
- preprint
- Published by MDPI AG in Preprints.org
Abstract
We were tasked by Canada’s COVID-19 Immunity Task Force to describe severe adverse events (SAE) associated with emergency department (ED) visits and/or hospitalizations in immune-mediated inflammatory diseases (IMID). At 8 Canadian centres, data were collected from adults with rheumatoid arthritis (RA), axial spondyloarthritis (AxS), systemic lupus (SLE), psoriatic arthritis (PsA) and inflammatory bowel disease (IBD). We administered questionnaires, analyzing SAEs experienced within 31 days following SARS-CoV-2 vaccination. About two-thirds (63%) of 1556 participants were female; mean age was 52.5 years. BNT162b2 (Pfizer) vaccine was the most common, with mRNA-1273 (Moderna) being second. Forty-nine percent of participants had IBD, 27.4% RA, 14.3% PsA, 5.3% SpA, and 4% SLE. Twelve SAEs leading to ED visit or hospitalization were self-reported, occurring in 11 participants. SAEs included 6 ED visits (including one Bell’s Palsy 31 days after first vaccination) and 6 hospitalizations (including one Guillain-Barré syndrome 15 days after the first vaccination). Two SAEs involved pericarditis, one in SLE (considered a serious disease flare) and one in RA. Thus, in the 31 days after SARS-CoV-2 vaccination in IMID, though several serious AEs occurred, these were relatively few. As SARS-CoV2 continues to be a common cause of death, our findings may help optimize vaccination acceptance.Keywords
All Related Versions
This publication has 13 references indexed in Scilit:
- Thromboembolism after Astra Zeneca COVID-19 vaccine: Not always PF4- antibody mediatedHuman Vaccines & Immunotherapeutics, 2023
- Adverse events following COVID‐19 mRNA vaccines: A systematic review of cardiovascular complication, thrombosis, and thrombocytopeniaImmunity, Inflammation and Disease, 2023
- COVID-19 vaccination in autoimmune diseases (COVAD) study: vaccine safety and tolerance in rheumatoid arthritisRheumatology, 2022
- Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adultsVaccine, 2022
- Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platformThe Lancet Rheumatology, 2022
- Local and systemic reactogenicity of COVID-19 vaccine BNT162b2 in patients with systemic lupus erythematosus and rheumatoid arthritisRheumatology International, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineNew England Journal of Medicine, 2020
- Trends in the Prevalence and Incidence of Psoriasis and Psoriatic Arthritis in Ontario, Canada: A Population‐Based StudyArthritis Care & Research, 2019
- Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studiesThe Lancet, 2017
- The Epidemiology of Rheumatoid Arthritis in Ontario, CanadaArthritis & Rheumatology, 2013